ArticleDigital health
Evaluation of symptom-management medications for predicting short-term survival in advanced cancer patients with machine learning.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Estimating the diverse symptoms of patients with advanced cancer is helpful for young physicians and medical teams in planning appropriate palliative care. We evaluated the use of medication, comorbidities, laboratory test results, and vital signs in hospitalized patients to predict death within 14 days. Methods: We retrospectively selected hospitalized patients with advanced cancer who were admitted to the hospice ward. We are using extreme gradient boosting (XGBoost) and a combination of random forest (RF) and XGBoost (RF-XGBoost) models to analyze sixteen comorbidities, eighteen types of medications, twenty-six laboratory tests, and six vital signs. Finally, SHapley Additive exPlanations (SHAP) analysis was employed to interpret the contribution of each feature to survival prediction. Results: Among the 2276 patients, 73% survived less than 14 days. The Area under the curve (AUC) of the XGBoost and RF-XGBoost models was 0.82 and 0.81 ( Conclusions: Our results suggest that the types of medications used by patients, especially stool softeners, antiemetics, and sedatives, are valuable in predicting survival beyond 14 days for hospitalized patients with advanced cancer. This result may assist young physicians and medical teams in developing appropriate palliative care plans for patients and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.